AstraZeneca has
signed a deal with US group G1 Therapeutics to test the potential of a new
combination therapy for lung cancer.
The parties have
signed a clinical trials collaboration that pairs AZ’ Tagrisso (osimertinib)
with G1’s oral CDK4/6 inhibitor G1T38 in EGFR mutation-positive non-small cell
lung cancer (NSCLC).
Under the
agreement, G1 will sponsor and conduct a Phase Ib/II study in collaboration
with AZ, scheduled to start in the first quarter of next year, in patients with
NSCLC who have experienced disease progression on first-line EGFR inhibitors
and carry the EGFR T790M mutation.
After
determining the recommended dose of the combination in the Phase Ib part of the
trial, the Phase II trial will then assess progression free survival in
patients given either Tagrisso monotherapy or Tagrisso plus G1T38.
“CDK4/6 inhibitors
can enhance the efficacy of targeted therapies, and G1T38 has already shown
encouraging preclinical and initial clinical data that support a potential
best-in-class profile,” noted Mark Velleca, G1’s chief executive.
“The addition of
G1T38 to Tagrisso in EGFR mutation-positive NSCLC has the potential to prolong
the time to disease progression by overcoming resistance mechanisms,” he added.
Source:
